Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5

(2023) Can Yue et al.   LANCET INFECTIOUS DISEASES

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1

(2023) Jessica Miller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

(2023) Ryuta Uraki et al.   LANCET INFECTIOUS DISEASES

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

(2023) Delphine Planas et al.   Nature Communications

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants

(2023) Panke Qu et al.   Cell Reports

Human Antibodies for Viral Infections

(2022) James E. Crowe   Annual Review of Immunology

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

(2022) Sho Iketani et al.   NATURE

An engineered bispecific human monoclonal antibody against SARS-CoV-2

(2022) Zhaohui Li et al.   NATURE IMMUNOLOGY

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

(2022) Kathryn Westendorf et al.   Cell Reports

Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies

(2022) Shane Miersch et al.   Cell Reports

Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron

(2022) Siling Wang et al.   Cell Reports

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern

(2022) Wenjuan Du et al.   Science Immunology

Designing antibodies as therapeutics

(2022) Paul J. Carter et al.   CELL

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

(2022) Aekkachai Tuekprakhon et al.   CELL

The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend

(2022) Perumal A. Desingu et al.   JOURNAL OF MEDICAL VIROLOGY

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

(2022) Qian Wang et al.   NATURE

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

(2022) Yunlong Cao et al.   NATURE

Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa

(2022) Houriiyah Tegally et al.   NATURE MEDICINE

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

(2022) Hualong Xiong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A counterintuitive antibody cocktail disrupts coxsackievirus

(2022) Seth J. Zost et al.   Cell Host & Microbe

Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail

(2022) Qingbing Zheng et al.   Cell Host & Microbe

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75

(2022) Qian Wang et al.   Cell Host & Microbe

Evasion of neutralising antibodies by omicron sublineage BA.2.75

(2022) Daniel J Sheward et al.   LANCET INFECTIOUS DISEASES

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage

(2022) Henning Gruell et al.   LANCET INFECTIOUS DISEASES

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

(2022) Zhiqiang Ku et al.   Nature Communications

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

(2022) Yingdan Wang et al.   Cell Discovery

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

(2022) Qian Wang et al.   CELL

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2

(2022) Panke Qu et al.   Cell Host & Microbe

Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations

(2022) Théophile Cocherie et al.   Microorganisms

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

(2021) C. Garrett Rappazzo et al.   SCIENCE

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

(2021) Chao Zhang et al.   Nature Communications

The prevalence of antibodies to SARS-CoV-2 among blood donors in China

(2021) Le Chang et al.   Nature Communications

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

(2021) Richard Copin et al.   CELL

Broad sarbecovirus neutralization by a human monoclonal antibody

(2021) M. Alejandra Tortorici et al.   NATURE

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

(2021) Tyler N. Starr et al.   NATURE

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

(2021) Jinhui Dong et al.   Nature Microbiology

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

(2021) Vincent Dussupt et al.   NATURE IMMUNOLOGY

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

(2021) David R. Martinez et al.   Science Translational Medicine

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants

(2021) Tingting Li et al.   Nature Communications

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants

(2021) Tingting Li et al.   Nature Communications

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

UCSF ChimeraX : Structure visualization for researchers, educators, and developers

(2020) Eric F. Pettersen et al.   PROTEIN SCIENCE

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

(2020) M. Alejandra Tortorici et al.   SCIENCE

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

(2020) Hejun Liu et al.   IMMUNITY

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody

(2020) Nicholas C. Wu et al.   PLoS Pathogens

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

(2017) Shawn Q Zheng et al.   NATURE METHODS

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

(2017) Ali Punjani et al.   NATURE METHODS

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

(2017) Thomas D. Goddard et al.   PROTEIN SCIENCE

Gctf: Real-time CTF determination and correction

(2016) Kai Zhang   JOURNAL OF STRUCTURAL BIOLOGY

Deciphering key features in protein structures with the new ENDscript server

(2014) Xavier Robert et al.   NUCLEIC ACIDS RESEARCH

Quantifying the local resolution of cryo-EM density maps

(2013) Alp Kucukelbir et al.   NATURE METHODS

Prevention of overfitting in cryo-EM structure determination

(2012) Sjors H W Scheres et al.   NATURE METHODS

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

MolProbity: all-atom structure validation for macromolecular crystallography

(2009) Vincent B. Chen et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY